The HER2 Diagnostic and Treatment Landscape in NSCLC - Identifying HER2-Directed NSCLC

Join us for an insightful episode of the Oncology Brothers podcast as we dive into the fast-evolving landscape of HER2-positive non-small cell lung cancer (NSCLC). In this first part of the two-part series, Drs. Rahul and Rohit Gosain were joined by Dr. Devika Das, a thoracic medical oncologist, and Dr. Fernando Lopez-Rios, a pathologist, to discuss the critical importance of testing and identifying HER2 alterations in lung cancer patients.

In this episode, we covered:
•⁠ ⁠The significance of HER2 alterations in NSCLC and how they differ from breast and gastric cancers.
•⁠ ⁠The complexities of biomarker testing, including NGS, IHC, and FISH amplification.
•⁠ ⁠Patient characteristics and phenotypes associated with HER2-positive disease.
•⁠ ⁠The current testing workflows in clinical practice and the role of liquid biopsies.
•⁠ ⁠Insights into the treatment landscape for HER2-positive NSCLC, including recent FDA approvals and ongoing clinical trials.

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the integration of precision medicine in lung cancer treatment.

Apple Podcast: https://podcasts.apple.com/us/podcast...
Spotify: https://creators.spotify.com/pod/prof...

Follow us on social media:
•⁠ ⁠X/Twitter:   / oncbrothers  
•⁠ ⁠Instagram:   / oncbrothers  
•⁠ Website: https://oncbrothers.com/

Don't forget to subscribe for the next episode, where we will explore treatment options for HER2-positive non-small cell lung cancer in greater detail!